Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H

J D Isaacs; B L Hazleman; K Chakravarty; J W Grant; G Hale; H Waldmann

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H

J Rheumatol. 1996 Jun;23(6):1103-6.

Authors

J D Isaacs¹, B L Hazleman, K Chakravarty, J W Grant, G Hale, H Waldmann

Affiliation

¹ Department of Rheumatology, Addenbrooke's NHS Trust, Cambridge, UK.

PMID: 8782148

Abstract

A worker in a polyvinyl chloride factory with rapidly progressive diffuse cutaneous scleroderma was treated with the humanized monoclonal antibody (Mab) CAMPATH-1H. Treatment was followed by rapid and substantial improvement in skin score, which was maintained during followup without additional therapy. The mode of action of CAMPATH-1H and its relationship to clinical improvement are discussed.

Publication types

Case Reports

MeSH terms

Adult
Alemtuzumab
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / therapeutic use*
Humans
Male
Occupational Diseases / etiology
Polyvinyl Chloride / adverse effects
Scleroderma, Systemic / chemically induced
Scleroderma, Systemic / pathology
Scleroderma, Systemic / therapy*
Skin Diseases / chemically induced
Skin Diseases / drug therapy*
Skin Diseases / pathology*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Alemtuzumab
Polyvinyl Chloride